Medication info
Rosetel Tablets 80/5/10 mg

Rosetel Tablets 80/5/10 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tabletEzetimibe›10mg / 1 tablet
Manufacturer / importer
Nokshim Pharmaceutical Co., Ltd.
Appearance
Orange oval film-coated tablet
Packaging
30 tablets/box [6 tablets/PTP X 5]
Approval status
Active

MFDS item code 202106688 · Approved 2021.09.29 · Insurance code 643606230

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, prevention of cardiovascular disease
Who takes it
Adults
Adult dose
This drug is for use only in adults. The dose should be individualized for each patient based on the efficacy and tolerability of telmisartan and the rosuvastatin/ezetimibe combination. Take 1 tablet once daily with water, with or without food. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. Telmisartan produces an additional blood pressure-lowering effect when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg of telmisartan orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting telmisartan to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. • Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin/ezetimibe The rosuvastatin/ezetimibe combination is administered once daily, with or without food. Patients should continue a standard cholesterol-lowering diet before and during treatment with the rosuvastatin/ezetimibe combination. The dose of the rosuvastatin/ezetimibe combination should be adjusted according to the patient's baseline LDL cholesterol level, recommended treatment goal, and response. Primary hypercholesterolemia The dose range of the rosuvastatin/ezetimibe combination is 5/10mg∼20/10mg once daily. The recommended initial dose is 5/10mg once daily. The dose may be adjusted for patients requiring a greater reduction in LDL cholesterol. After starting the rosuvastatin/ezetimibe combination or adjusting the dose, measure blood lipid levels at intervals of at least 4 weeks and adjust the dose accordingly; the dose may be increased to a maximum of 20/10mg once daily. For patients taking telmisartan and the rosuvastatin/ezetimibe combination concomitantly, switching to this drug (a combination tablet containing the same amounts of each active ingredient) may be considered for convenience.

Ingredients

Manufacturer
Nokshim Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, prevention of cardiovascular disease

  • Primary hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attack
  • clinical evidence of damage to peripheral organs
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial dyslipidemia
  • non-familial dyslipidemia
  • mixed dyslipidemia
  • elevated total cholesterol
View approved original text

This medication is used for patients who need to take Telmisartan and Rosuvastatin/Ezetimibe simultaneously. Telmisartan helps lower the risk of myocardial infarction, stroke, and death due to cardiovascular disease in high-risk patients, alongside the treatment of primary hypertension. It is especially recommended for patients over 55 years of age at risk of cardiovascular diseases who cannot use ACE inhibitors. Rosuvastatin/Ezetimibe is used as an adjunct to diet to improve cholesterol and triglyceride levels in patients with primary hypercholesterolemia and mixed dyslipidemia, and to increase HDL cholesterol levels. Therefore, this medication is used to enhance cardiovascular health by managing both blood pressure and cholesterol simultaneously.

How to take

Adult dose

This drug is for use only in adults. The dose should be individualized for each patient based on the efficacy and tolerability of telmisartan and the rosuvastatin/ezetimibe combination. Take 1 tablet once daily with water, with or without food. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. Telmisartan produces an additional blood pressure-lowering effect when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg of telmisartan orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting telmisartan to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. • Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin/ezetimibe The rosuvastatin/ezetimibe combination is administered once daily, with or without food. Patients should continue a standard cholesterol-lowering diet before and during treatment with the rosuvastatin/ezetimibe combination. The dose of the rosuvastatin/ezetimibe combination should be adjusted according to the patient's baseline LDL cholesterol level, recommended treatment goal, and response. Primary hypercholesterolemia The dose range of the rosuvastatin/ezetimibe combination is 5/10mg∼20/10mg once daily. The recommended initial dose is 5/10mg once daily. The dose may be adjusted for patients requiring a greater reduction in LDL cholesterol. After starting the rosuvastatin/ezetimibe combination or adjusting the dose, measure blood lipid levels at intervals of at least 4 weeks and adjust the dose accordingly; the dose may be increased to a maximum of 20/10mg once daily. For patients taking telmisartan and the rosuvastatin/ezetimibe combination concomitantly, switching to this drug (a combination tablet containing the same amounts of each active ingredient) may be considered for convenience.

Precautions

This medication can cause serious harm to the fetus or newborn when taken during pregnancy, so it must be stopped immediately if pregnancy is confirmed. Muscle-related side effects, such as myalgia or rhabdomyolysis, may occur rarely, so if severe muscle pain or weakness is felt, consultation with a doctor should be sought immediately. Due to potential effects on liver function, this medication should not be taken by patients with liver disease or elevated liver enzyme levels, and liver function tests should be done regularly while taking this medication. Patients with impaired kidney function or certain cardiovascular diseases should consult a doctor before taking this medication and, if necessary, periodically check kidney function and blood pressure. Patients with allergies to any component of this medication or those with specific genetic metabolic disorders should not take it. There may be interactions with other medications, so if you are currently taking other medications, be sure to inform your healthcare provider. It is advisable to avoid or limit alcohol consumption while taking this medication, and caution should be exercised as dizziness or drowsiness may occur during driving or operating machinery. If symptoms such as muscle pain, rash, breathing difficulties, swelling of the face or lips occur, cease taking the medication immediately and consult your healthcare provider. This medication should be used in conjunction with a proper diet, and continuous lifestyle improvements are particularly necessary for controlling cholesterol levels. Elderly or diabetic patients may be at higher risk for adverse reactions and should be observed more carefully.

Side effects

Increased ALT, Increased AST, Increased Ɣ-GTP, Increased ALP, Abdominal pain, Oral ulcers, Vomiting, Chest pain, Palpitations, Dizziness, Difficulty breathing, Functional impairment of the Eustachian tube, Tympanic membrane perforation, Acute kidney injury, Hematuria, Herpes zoster, Pneumonia, Non-small cell lung cancer, Hair loss, Dysuria, Rhinitis, Pharyngeal discomfort, Lung disease, Unspecified gastrointestinal disease, Benign gastrointestinal neoplasm, Hemorrhoids, Skeletal pain, Osteoporosis, Sensory loss, Movement disorders, Atherosclerosis, Increased frequency of urination, Tinnitus, Hearing loss, Bad breath, Fatty liver, Chest pain, Facial swelling, Strange feeling, Drug intolerance, Irritable bowel syndrome, Esophagitis, Somnolence, Neurodegenerative disorders, Orthostatic dizziness, Migraine, Diabetes mellitus, Impaired glucose tolerance, Depression, Bronchitis, Cystitis, Onychomycosis, Soft tissue infection, Liver steatosis, Liver dysfunction, Hepatotoxicity, Acute hepatitis, Toxic hepatitis, Increased gamma-glutamyl transferase, Elevated blood cholesterol, Increased serum alkaline phosphatase, Irregular heart rate, Osteoarthritis, Musculoskeletal stiffness, Musculoskeletal discomfort, Muscle weakness, Cold sweats, Dermatitis, Skin burning sensation, Skin disorders, Alopecia, Oropharyngeal pain, Nasal congestion, Respiratory disorders, Pelvic pain, Breast cysts, Ptosis, Diabetic retinopathy, Ear discomfort, Renal dysfunction, Benign esophageal neoplasm, Headache, Facial spasms, Sensory abnormalities, Paralysis, Cough, Hyperventilation, Pneumonia, Flushing, Erectile dysfunction, Weakness, Edema, Decreased libido, Facial edema, Rash, Alopecia, Conjunctivitis, Tinnitus, Petechiae, Anemia, Thrombocytopenia, Elevated serum creatinine, Increased uric acid in the blood, Elevated creatine kinase, Decreased hemoglobin, Constipation, Nausea, Pancreatitis, Itching, Rash and hives, Myalgia, Myopathy, Rhabdomyolysis, Weakness, Polyneuropathy, Amnesia, Peripheral neuropathy, Diarrhea, Jaundice, Hepatitis, Stevens-Johnson syndrome, Eosinophilia with systemic symptoms drug reaction syndrome, Lupus-like syndrome, Muscle rupture, Arthralgia, Immune-mediated necrotizing myopathy, Hematuria, Edema, Depression, Sleep disorders, Gynecomastia, Fatal and non-fatal liver failure, Memory decline, Forgetfulness, Amnesic syndrome, Memory impairment, Confusion, Severe muscle weakness, Ocular muscle weakness

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to protect it from air and moisture. It is best to maintain storage temperatures between 1°C and 30°C. This will help preserve the effectiveness and safety of the medication.

Appearance and packaging

Appearance

Orange oval film-coated tablet

Package unit

30 tablets/box [6 tablets/PTP X 5]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.